AP
Aptevo Therapeutics Inc.
APVO · NASDAQ
$1.84 -2.13% (-$0.04)
1M -23.65%
Market Cap $2.29M
P/E Ratio -
Div. Yield -
ROE 201.49%
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.38x
P/E N/A
EV/EBITDA N/A
Growth
19 /100
Declining Book val. growth 1.11%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 262.30%
ROE 201.49%
ROA 181.89%
Debt
79 /100
Low Debt/Equity 0.70x
Current ratio 2.08x
Int. coverage N/A
Stability
10 /100
Unstable Beta 1.61x
EPS volatility 166.54%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about APVO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jeffrey G. Lamothe
Employees
33
Headquarters
Seattle
Upcoming events
05 NOV
Earnings
Upcoming earnings report